Sign in
4

Changes in Ownership

Mineralys Therapeutics, Inc. Filed Acc 0001816952-26-000005

Director sold 3,000 shares at $28.58 ($85,740)

  • Director acquired 3,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Karydas Daphne · Director

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2026-09-15 Exercise or conversion : show line 1 in the form 10b5-1 +3,000 $12.02 $36,060 9,200 D
2026-09-15 Sale : show line 2 in the form 10b5-1 −3,000 $28.58 $85,740 6,200 D
Open-market sales · 3,000 sh · avg $28.58 · $85,740

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-09-15 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option −3,000 35,000 D
Loading xslF345X06/wk-form4_1789681270.xml…